ShubhamPantMD

Associate Professor of Medicine & Director of Clinical Trials, Hematology/Oncology Section of the Stephenson Cancer Center in Oklahoma City.

Join to view full profile

Dr. Pant is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Pant's full profile

Already have an account?

Office
1515 Holcombe Blvd
Oklahoma City, OK 77030
Phone+1 405-271-8299
Is this information wrong?

Education & Training

Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2005 - 2008
University of Oklahoma Health Sciences CenterResidency, Internal Medicine, 2002 - 2005
Maulana Azad Medical CollegeClass of 2001

Certifications & Licensure

FL State Medical License 2021 - Present
OK State Medical License 2004 - 2025
WA State Medical License 2023 - 2025
AL State Medical License 2023 - 2024
LA State Medical License 2023 - 2024
GA State Medical License 2023 - 2024
AZ State Medical License 2023 - 2024
TX State Medical License 2015 - 2024
MS State Medical License 2023 - 2024
TN State Medical License 2023 - 2024
OH State Medical License 2005 - 2010
Join now to see all

Clinical Trials

Cytogenetic Studies in Acute Leukemia and Multiple Myeloma Start of enrollment: 1984 Jun 01
Active, not recruiting
Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
Completed
Phase 3
Androgen Ablation Therapy With or Without Chemotherapy in Treating Patients With Metastatic Prostate Cancer Start of enrollment: 2006 Sep 26
Active, not recruiting
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery Start of enrollment: 2007 Jun 01
Active, not recruiting
Phase 3
Surgery With or Without Docetaxel and Leuprolide or Goserelin in Treating Patients With High-Risk Localized Prostate Cancer Start of enrollment: 2007 May 08
Active, not recruiting
Phase 3
Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Start of enrollment: 2008 Aug 08
Active, not recruiting
Phase 3
Sunitinib Malate as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Previously Treated With Combination Chemotherapy Start of enrollment: 2008 Jun 15
Completed
Phase 3
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer Start of enrollment: 2008 Oct 13
Completed
Phase 3
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery Start of enrollment: 2009 May 15
Active, not recruiting
Phase 2
Collecting and Storing Blood, Bone Marrow, and Other Samples From Patients With Acute Leukemia, Chronic Leukemia, or Myelodysplastic Syndromes Start of enrollment: 1996 May 01
Active, not recruiting
Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Start of enrollment: 2009 Jul 15
Completed
Phase 3
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2009 Oct 28
Completed
Phase 3
Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer Start of enrollment: 2010 Feb 15
Completed
Phase 3
Donor Stem Cell Transplant in Treating Patients With High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2010 Feb 01
Completed
Phase 2
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnos Start of enrollment: 2011 Jan 01
Gemcitabine Hydrochloride or Pemetrexed Disodium and Carboplatin With or Without Celecoxib in Treating Patients With Advanced Non-Small Cell Lung Cancer Start of enrollment: 2010 Feb 01
Terminated
Phase 3
Calcium Gluconate and Magnesium Sulfate in Preventing Neurotoxicity in Patients With Colon Cancer or Rectal Cancer Receiving Oxaliplatin-Based Combination Chemotherapy Start of enrollment: 2010 Jun 01
Completed
Phase 3
Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery Start of enrollment: 2010 Jun 01
Active, not recruiting
Phase 3
Everolimus With or Without Bevacizumab in Treating Patients With Advanced Kidney Cancer That Progressed After First-Line Therapy Start of enrollment: 2010 Sep 15
Terminated
Phase 3
Vitamin D and Breast Cancer Biomarkers in Female Patients Start of enrollment: 2010 Oct 01
Completed
Phase 3
Everolimus and Octreotide Acetate With or Without Bevacizumab in Treating Patients With Locally Advanced or Metastatic Pancreatic Neuroendocrine Tumors That Cannot Be Removed by Surgery Start of enrollment: 2010 Oct 15
Completed
Phase 2
Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer Start of enrollment: 2011 May 16
Completed
Not Applicable
E7050 in Combination With Sorafenib Versus Sorafenib Alone as First Line Therapy in Participants With Hepatocellular Carcinoma Start of enrollment: 2011 Jul 19
Completed
Phase 1, Phase 2
Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer Start of enrollment: 2011 Jan 15
Active, not recruiting
Phase 3
Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by Surgery Start of enrollment: 2011 May 25
Active, not recruiting
Phase 3
Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
Active, not recruiting
Phase 3
FOLFIRINOX in Patients With Inoperable Pancreatic Cancer Start of enrollment: 2011 May 01
Terminated
Phase 2
PROSPECT: Chemotherapy Alone or Chemotherapy Plus Radiation Therapy in Treating Patients With Locally Advanced Rectal Cancer Undergoing Surgery Start of enrollment: 2012 Jun 12
Active, not recruiting
Phase 2, Phase 3
A Phase 1b/2 Study of OMP-59R5 (Tarextumab) in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer Start of enrollment: 2012 Oct 01
Completed
Phase 1, Phase 2
Cabozantinib-s-malate or Sunitinib Malate in Treating Patients With Previously Untreated Locally Advanced or Metastatic Kidney Cancer Start of enrollment: 2013 Jul 08
Completed
Phase 2
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer Start of enrollment: 2013 May 01
Terminated
Phase 3
PEGPH20 Plus Nab-Paclitaxel Plus Gemcitabine Compared With Nab-Paclitaxel Plus Gemcitabine in Participants With Stage IV Untreated Pancreatic Cancer Start of enrollment: 2013 May 14
Completed
Phase 2
First-in-human Study of CA102N Monotherapy and CA102N Combined With Trifluridine/Tipiracil (LONSURF) in Subjects With Advanced Solid Tumors Start of enrollment: 2019 Apr 09
Completed
Phase 1
Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors Start of enrollment: 2019 Jan 10
Terminated
Phase 1, Phase 2
Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma Start of enrollment: 2021 Jan 25
Active, not recruiting
Phase 1
A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies Start of enrollment: 2019 Nov 06
Active, not recruiting
Phase 1
A Study to Test Different Doses of BI 1701963 Alone and Combined With Trametinib in Patients With Different Types of Advanced Cancer (Solid Tumours With KRAS Mutation) Start of enrollment: 2019 Oct 28
Active, not recruiting
Phase 1
A Multi-center Trial to Evaluate Multiple Regimens in Metastatic Pancreatic Cancer Start of enrollment: 2020 Jan 31
Active, not recruiting
Phase 3
A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers Start of enrollment: 2020 Oct 01
Active, not recruiting
Phase 2
Join now to see all

Publications & Presentations

PubMed

Trends Over Time in Recurrence Patterns and Survival Outcomes after Neoadjuvant Therapy and Surgery for Pancreatic Cancer.
Laura R Prakash, Samuel H Cass, Ching-Wei D Tzeng, Jessica Maxwell, Rebecca A Snyder, Michael P Kim, Ryan W Huey, Brandon G Smaglo, Shubham Pant, Eugene J Koay, Robert...> ;Annals of Surgery. 2024 Mar 20
Co-Clinical Trial of Novel Bispecific Anti-HER2 Antibody Zanidatamab in Patient-Derived Xenografts.
DiPeri, T., Evans, K., Wang, B., Zhao, M., Akcakanat, A., Raso, M., Rizvi, Y., Zheng, X., Korkut, A., Varadarajan, K., Uzunparmak, B., Dumbrava, E., Pant, S., Ajani, J...> ;Cancer Discovery. 2024 Feb 15
Phase I Study of mTORC1/2 Inhibitor Sapanisertib (CB-228/TAK-228) in Combination with Metformin in Patients with mTOR/AKT/PI3K Pathway Alterations and Advanced Solid M...
Subbiah, V., Coleman, N., Piha-Paul, S., Tsimberidou, A., Janku, F., Rodon, J., Pant, S., Dumbrava, E., Fu, S., Hong, D., Zhang, S., Sun, M., Jiang, Y., Roszik, J., So...> ;Cancer Research Communications. 2024 Feb 12
Methylthioadenosine Phosphorylase Genomic Loss in Advanced Gastrointestinal Cancers.
Ngoi, N., Tang, T., Gaspar, C., Pavlick, D., Buchold, G., Scholefield, E., Parimi, V., Huang, R., Janovitz, T., Danziger, N., Levy, M., Pant, S., De Armas, A., Kumpula...> ;The Oncologist. 2024 Feb 8
1 citations
Impact of KRAS mutations and co-mutations on clinical outcomes in pancreatic ductal adenocarcinoma.
Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, Kawther Abdilleh, Mark Knafl, Paul Edelkamp, Kristin Alfaro-Munoz, Ray Chacko, Jennifer Peterson, Brandon G Smagl...> ;NPJ Precision Oncology. 2024 Feb 3
1 citations
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma.
Amaria, R., Knisely, A., Vining, D., Kopetz, S., Overman, M., Javle, M., Antonoff, M., Tzeng, C., Wolff, R., Pant, S., Lito, K., Rangel, K., Fellman, B., Yuan, Y., Lu,...> ;Journal for Immunotherapy of Cancer. 2024 Feb 2
3 citations
Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial.
Devoe, C. E., Shubham Pant, Zev A Wainberg, Colin D Weekes, Muhammad Furqan, Pashtoon M Kasi, Craig E Devoe, Alexis D Leal, Vincent Chung, Olca Basturk, Haley VanWyk, ...> ;Nature Medicine. 2024 Feb 1
NCI10066: a Phase 1/2 study of olaparib in combination with ramucirumab in previously treated metastatic gastric and gastroesophageal junction adenocarcinoma.
Michael Cecchini, James M Cleary, Yu Shyr, Joseph Chao, Nataliya Uboha, May Cho, Anthony Shields, Shubham Pant, Laura Goff, Kristen Spencer, Edward Kim, Stacey Stein, ...> ;British Journal of Cancer. 2024 Feb 1
2 citations
Stereotactic body radiotherapy with or without selective dismutase mimetic in pancreatic adenocarcinoma: an adaptive, randomised, double-blind, placebo-controlled, pha...
Cullen M Taniguchi, Jessica M Frakes, Todd A Aguilera, Manisha Palta, Brian Czito, Manoop S Bhutani, Lauren E Colbert, Joseph Abi Jaoude, Vincent Bernard, Shubham Pant...> ;The Lancet. Oncology. 2023 Dec 1
14 citations
NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phas...
Zev A Wainberg, Davide Melisi, Teresa Macarulla, Roberto Pazo Cid, Sreenivasa R Chandana, Christelle De La Fouchardière, Andrew Dean, Igor Kiss, Woo Jin Lee, Thorsten ...> ;Lancet. 2023 Oct 7
Impact ofMutations and Co-mutations on Clinical Outcomes in Pancreatic Ductal Adenocarcinoma.
Abdelrahman Yousef, Mahmoud Yousef, Saikat Chowdhury, Kawther Abdilleh, Mark Knafl, Paul Edelkamp, Kristin Alfaro-Munoz, Ray Chacko, Jennifer Peterson, Brandon G Smagl...> ;Research Square. 2023 Aug 10
13 citations
Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study.
Shubham Pant, Martin Schuler, Gopa Iyer, Olaf Witt, Toshihiko Doi, Shukui Qin, Josep Tabernero, David A Reardon, Christophe Massard, Anna Minchom, Iwona Lugowska, Omar...> ;The Lancet. Oncology. 2023 Aug 1
2 citations
Discordance of HER2 Expression and/or Amplification on Repeat Testing.
Timothy P DiPeri, Kathleen Kong, Kaushik Varadarajan, Daniel D Karp, Jaffer A Ajani, Shubham Pant, Michael F Press, Sarina A Piha-Paul, Ecaterina E Dumbrava, Funda Mer...> ;Molecular Cancer Therapeutics. 2023 Aug 1
A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 ...
Sarina A Piha-Paul, Chieh Tseng, Hai T Tran, Meng Gao, Daniel D Karp, Vivek Subbiah, Apostolia Maria Tsimberidou, Jitesh D Kawedia, Siqing Fu, Shubham Pant, Timothy A ...> ;Cancer Chemotherapy and Pharmacology. 2023 Aug 1
A Phase I Trial of Bevacizumab and Temsirolimus in Combination With Valproic Acid in Advanced Solid Tumors.
Blessie Elizabeth Nelson, Apostolia M Tsimberidou, Xueyao Fu, Siqing Fu, Vivek Subbiah, Anil K Sood, Jordi Rodon, Daniel D Karp, George Blumenschein, Scott Kopetz, Shu...> ;The Oncologist. 2023 Dec 11
18 citations
Zanidatamab for HER2-amplified, unresectable, locally advanced or metastatic biliary tract cancer (HERIZON-BTC-01): a multicentre, single-arm, phase 2b study.
James J Harding, Jia Fan, Do-Youn Oh, Hye Jin Choi, Jin Won Kim, Heung-Moon Chang, Lequn Bao, Hui-Chuan Sun, Teresa Macarulla, Feng Xie, Jean-Phillippe Metges, Jie'er ...> ;The Lancet. Oncology. 2023 Jul 1
1 citations
Utility of Established Prognostic Scoring Systems for Patients with Advanced Pancreatic Adenocarcinoma Enrolled in Immunotherapy-Based Early-Phase Clinical Trials.
Rishi Surana, Graciela Nogueras Gonzalez, Jane Rogers, David S Hong, Timothy A Yap, Jordi Rodon, Aung Naing, Robert A Wolff, Brandon G Smaglo, Funda Meric Bernstam, Vi...> ;Journal of Gastrointestinal Cancer. 2023 Dec 1
20 citations
Adagrasib in Advanced Solid Tumors Harboring aMutation.
Tanios S Bekaii-Saab, Rona Yaeger, Alexander I Spira, Meredith S Pelster, Joshua K Sabari, Navid Hafez, Minal Barve, Karen Velastegui, Xiaohong Yan, Aditya Shetty, Hir...> ;Journal of Clinical Oncology. 2023 Sep 1
2 citations
The Emerging Role of Circulating Tumor DNA in Non-Colorectal Gastrointestinal Cancers.
Michael S Lee, Ahmed O Kaseb, Shubham Pant> ;Clinical Cancer Research. 2023 Sep 1
1 citations
Phase I study of sapanisertib with carboplatin and paclitaxel in mTOR pathway altered solid malignancies.
Omar Alhalabi, Roman Groisberg, Ralph Zinner, Andrew W Hahn, Aung Naing, Shizhen Zhang, Apostolia M Tsimberidou, Jordi Rodon, Siqing Fu, Timothy A Yap, David S Hong, M...> ;NPJ Precision Oncology. 2023 Apr 18
2 citations
Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101).
Roberto Carmagnani Pestana, Justin T Moyers, Jason Roszik, Shiraj Sen, David S Hong, Aung Naing, Cynthia E Herzog, Siqing Fu, Sarina A Piha-Paul, Jordi Rodon, Timothy ...> ;Clinical Cancer Research. 2023 May 1
4 citations
Effects of a Pragmatic Home-based Exercise Program Concurrent With Neoadjuvant Therapy on Physical Function of Patients With Pancreatic Cancer: The PancFit Randomized ...
An T Ngo-Huang, Nathan H Parker, Lianchun Xiao, Keri L Schadler, Maria Q B Petzel, Laura R Prakash, Michael P Kim, Ching-Wei D Tzeng, Jeffrey E Lee, Naruhiko Ikoma, Ro...> ;Annals of Surgery. 2023 Jul 1
2 citations
Phase 1b study of pan-AKT inhibitor vevorisertib alone or with paclitaxel or fulvestrant in PIK3CA/AKT/PTEN-mutated advanced solid tumors.
Shubham Pant, Erika Hamilton, Susanna V Ulahannan, James F Strauss, Fadi S Braiteh, Mo Huang, Danny Chih Hsun Liaw> ;Cancer. 2023 Jun 15
A phase 1/2a safety, pharmacokinetics, and efficacy study of the novel nucleoside analog FF-10502-01 for the treatment of advanced solid tumors.
Filip Janku, Milind M Javle, Shiraj Sen, Shubham Pant, Lindsay G Bramwell, Vivek Subbiah, Tracey Way, David S Wages, Catherine A Wheeler, Takeaki Suzuki, Kazunori Saek...> ;Cancer. 2023 May 15
Predictors of Oncologic Outcome in Patients Receiving Phase I Investigational Therapy for Recurrent or Metastatic Cervical Cancer.
Son, J., Lin, H., Fu, S., Biter, A., Dumbrava, E., Karp, D., Naing, A., Pant, S., Piha-Paul, S., Rodon, J., Subbiah, V., Tsimberidou, A., Yap, T., Frumovitz, M., Jazae...> ;Journal of Immunotherapy and Precision Oncology. 2023 Feb 1
Join now to see all

Journal Articles

Response and Survival Associated with First-Line FOLFIRINOX vs Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal Adenocarcinoma
Shubham Pant, Milind Javle, Naruhiko Ikoma, Ching-Wei Tzeng, Jeffrey E Lee, JAMA Surgery

Lectures

Tyme-88-Panc Part 2: A randomized phase II/III of SM-88 with MPS as third-line in metastatic PDAC.
ASCO Gastrointestinal Cancers Symposium - San Francisco, CA - 1/24/2020
A phase I dose escalation (DE) study of ERK inhibitor, LY3214996, in advanced (adv) cancer (CA) patients (pts).
2019 ASCO Annual Meeting - 6/1/2019
A phase I/II study of live biotherapeutic MRx0518 in combination with pembrolizumab in patients who have progressed on prior anti-PD-1 therapy.
2019 ASCO Annual Meeting - 6/1/2019
Evaluation of the spectrum selective RTK inhibitor sitravatinib in clear cell renal cell carcinoma (ccRCC) refractory to anti-angiogenic therapy (AAT).
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018
Join now to see all

Other

Evaluation and management of aromatase inhibitor-induced bone loss
Pant S, Shapiro CL
http://www.uptodate.com/contents/evaluation-and-management-of-aromatase-inhibitor-induced-bone-loss
UpToDate, Wolters Kluwer Health - 2012-08-29

Authored Content

Response and Survival Associated with First-Line FOLFIRINOX vs Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaJuly 2020
Response and Survival Associated with First-Line FOLFIRINOX vs Gemcitabine and Nab-Paclitaxel Chemotherapy for Localized Pancreatic Ductal AdenocarcinomaJuly 2020